IRONWOOD PHARMACEUTICALS, INC. Deferred Income Tax Expense (Benefit)
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Deferred Income Tax Expense (Benefit) of $40.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-26
- IRONWOOD PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2022-12-31 was $20.13M, a 941.33% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2022-09-30 was $16.02M, a 522.46% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2022-06-30 was $14.89M.
- IRONWOOD PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2022-03-31 was $14.71M.
- IRONWOOD PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2025 was $40.80M, a 40.04% decline from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2024 was $68.05M, a 6.21% decline from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2023 was $72.56M, a 10.37% increase from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2022 was $65.74M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $40.80M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $68.05M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $72.56M 10-K · filed 2025-03-31 | |||
| 2022-12-31 | $20.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $36.15M derived: sum of 2 quarters · filed 2025-03-31 | $51.03M derived: sum of 3 quarters · filed 2025-03-31 | $65.74M 10-K · filed 2025-03-31 |
| 2022-09-30 | $16.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $30.90M derived: sum of 2 quarters · filed 2022-11-03 | $45.61M 10-Q · filed 2022-11-03 | $47.54M derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-06-30 | $14.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $29.59M 10-Q · filed 2022-08-04 | $31.53M derived: sum of 3 quarters · filed 2024-02-16 | $34.10M derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-03-31 | $14.71M 10-Q · filed 2022-05-05 | $16.64M derived: sum of 2 quarters · filed 2024-02-16 | $19.21M derived: sum of 3 quarters · filed 2024-02-16 | |
| 2021-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $4.51M derived: sum of 2 quarters · filed 2024-02-16 | -$333.29M 10-K · filed 2024-02-16 | |
| 2021-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$335.23M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$337.80M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |